About Celltrion

Celltrion Inc. was founded in South Korea in 1999 and specialises in the development of high-quality antibodies, in particular biosimilars. The company entered the global market in this field in 2015 with the development of the first biosimilar monoclonal antibody (derived from a single cell line). Today, together with its Celltrion Healthcare branch, Celltrion Inc. can offer research, development, production and distribution all from a single source. This means that Celltrion can now offer its affordable solutions for forward-thinking therapies in 120 countries with more than 30 different local partners or its own distribution centres – including the German sales branch Celltrion Healthcare Deutschland GmbH based in Bad Homburg.

Constant investment

In order to keep breaking new ground, improving therapies and developing further, Celltrion focuses on continuous investment in its own research and (clinical) studies. The company also has one of the world's largest, state-of-the-art mammalian cell culture facilities, designed in accordance with the GMP standards of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). With a wide-ranging and ever-growing portfolio of biosimilars and biologics, Celltrion has the potential to continuously improve the supply of monoclonal antibodies to treat a variety of diseases - for example autoimmune diseases or cancer.

Why biosimilars?

Since the late 1980s, technical advances have enabled the use of biologics as a highly effective treatment option for patients and healthcare providers. This opens up a whole new world of possibilities for targeted treatment for a range of diseases such as autoimmune diseases, cancer and chronic illnesses. Biologics, and in particular monoclonal antibodies, are among the fastest-growing branches within the pharmaceutical industry. With their unique mechanism, they specifically target the triggers of the disease symptoms. Should the immune system react in an exaggerated or undesired way, they prevent signals from being passed on within the body that trigger inflammation. However, although monoclonal antibodies have already helped a lot of patients, these highly effective drugs remained out of reach for many more due to their high price until the introduction of biosimilars. High-quality biosimilars now offer a more cost-effective alternative. 

Memberships

In order to support patients with chronic inflammatory diseases beyond the (further) development of biotechnologically produced drugs, Celltrion Healthcare is networked with several associations as a supporting member: Celltrion Healthcare is currently a supporting member of